CClinicalTrials.gg
Status unknownNCT03403985Updated Sep 25, 2019

Long-term Evaluation of Direct Pulp Capping

An interventional study of Calcium Hydroxide (Ca(OH)2) and Mineral Trioxide Aggregate in Dental Pulp Capping and Dental Caries Extending to Pulp, sponsored by Jordan University of Science and Technology. Status unknown at 1 site in Jordan. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by Jordan University of Science and Technology · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2019), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

Calcium hydroxide and mineral trioxide aggregate have been used in vital pulp therapy with variable outcomes recorded by different study. They will be compared when used for direct pulp capping in cariously exposed mature permanent teeth.

Read the detailed description

Vital pulp therapy has the benefit of providing patients with a conservative treatment option with relatively low cost when compared to conventional root canal treatment and spares them possible post-treatment consequences that might occur. Vital pulp treatment in trauma cases is associated with high success rate but controversy still exists regarding vital pulp treatment in carious-exposed pulp.

The purpose of this study is to evaluate the success rate of direct pulp capping performed with MTA-Angelus® or calcium hydroxide in mechanical-exposed or carious-exposed mature permanent human teeth. Patients included in this study will be recruited from routine dental patients attending conservative clinics in JUST Dental Teaching Centre. Adult patients scheduled for routine conservative treatment involving caries removal and restoration with mechanical or carious pulp exposure will be invited to participate in this study.

A total of 80 carious human teeth with carious pulp exposure will be included in this randomized clinical study. Patients are among those scheduled for conservative dental treatment and end with pulp exposure. The patients and/or their parents will be asked to sign a consent form after receiving a detailed explanation about the study rationale, clinical procedures, and possible risks. The exposed teeth will be divided randomly into two experimental groups (n=40) according to the dressing materials; MTA-Angelus® or calcium hydroxide, then teeth will be restored with permanent filling. Teeth will be reviewed recording any signs and symptoms. Patients will be reviewed in 1 week, 3 months and yearly after. MTA-Angelus and calcium hydroxide are anticipated to be biocompatible and induce hard tissue barrier. This project will reveal if tested materials are presented with promising profile upon using as direct pulp capping dressing in mechanical and carious-exposed pulp.

02

Conditions studied

  • Dental Pulp Capping
  • Dental Caries Extending to Pulp

Browse trials for

03

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. carious teeth that had no previous root canal treatment
  2. Pulpal diagnosis of normal or reversible pulpitis

Exclusion criteria

Exclusion Criteria:

  1. History of irreversible pulpal pain
  2. Immature teeth
  3. Non restorable teeth
  4. Teeth with active periodontal disease
  5. History of any systemic disease
  6. Concurrent medication with systemic steroids, antibiotics, analgesics, immunomodulatory drugs or cytotoxics
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    calcium hydroxide direct pulp capping

    calcium hydroxide (Ca(OH)2 direct pulp capping will be performed in this group

    Drug: Calcium Hydroxide (Ca(OH)2)

  • Experimental
    MTA direct pulp capping

    Mineral Trioxide Aggregate (MTA) direct pulp capping will be performed in this group

    Drug: Mineral Trioxide Aggregate

Interventions

  • DrugCalcium Hydroxide (Ca(OH)2)

    Ca(OH)2 will be used in this group

    Also known as: Ca(OH)2

  • DrugMineral Trioxide Aggregate

    MTA will be used in this group

    Also known as: MTA

05

What researchers measure

Primary outcomes

  1. clinical vital pulp therapy success

    Treatment was considered successful based on the absence of symptoms and signs Treatment was considered successful based on absence of symptoms and signs

    Time frame: from date of randomization until failure reported for up to 100 months

Secondary outcomes

  1. Radiographic success

    treatment could be further evaluated based on the absence of canal oblitration

    Time frame: from date of randomization until failure reported for up to 100 months

06

Study locations

1 site
  • Dental health center
    Irbid, Jordan
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03403985
Lead sponsor
Jordan University of Science and Technology
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Jun 1, 2017
Primary completion
Jun 28, 2017
Completion
Jun 2022 (estimated)
Last update
Sep 25, 2019

Study contacts

Lama Awawdeh, PhD
principal investigator · Jordan University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion